Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9819484 | 0.84 | L3MBTL1 (0.48) | L3MBTL1KMT2AMEN1POLBMAPT | |
| SCHEMBL15147751 | 0.81 | PDE5A (0.65) | L3MBTL1HPGDKDM4EALDH1A1GBA1 | |
| SCHEMBL28408860 | 0.81 | KDM4E (0.53) | L3MBTL1KMT2AMEN1POLBMAPT | |
| SCHEMBL20610507 | 0.81 | KMT2A (0.59) | L3MBTL1KMT2AMEN1POLBMAPT | |
| SCHEMBL1995850 | 0.80 | NR1I3 (0.56) | POLBMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL638096 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KMT2AMEN1POLBMAPT | |
| SCHEMBL28407301 | 0.79 | KMT2A (0.49) | L3MBTL1KMT2AMEN1POLBMAPT | |
| Hydrochloric Acid SCHEMBL28406920 | 0.79 | CYP1B1 (0.44) | L3MBTL1TSHRKDM4EALDH1A1GBA1 | |
| SCHEMBL7673162 | 0.78 | MEN1 (0.83) | L3MBTL1KMT2AMEN1POLBMAPT | |
| SCHEMBL4542917 | 0.77 | NUDT1 (0.57) | L3MBTL1KMT2AMEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| EP-1716151-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005095406-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
| EP-0028473-B1 | CHLORO- AND ALKOXY-SUBSTITUTED-2,4-DIAMINOQUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-09 | — | — | EP | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K1 | L3MBTL1 2913/4885KMT2A 2064/4885MEN1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.